Simvastatin in Colorectal Surgery (StatCol)
Primary Purpose
Intestinal Neoplasm, Perioperative Care
Status
Completed
Phase
Phase 3
Locations
New Zealand
Study Type
Interventional
Intervention
Simvastatin
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Intestinal Neoplasm focused on measuring Statin, Colon, Colorectal, Intestinal Neoplasms, ERAS, Perioperative Care
Eligibility Criteria
Inclusion criteria:
- Consecutive consenting patients undergoing elective colectomy, rectal resection, and reversal of Hartmann's procedure at Middlemore Hospital, Manukau Surgery Centre, Auckland City Hospital, and North Shore Hospital.
Exclusion criteria:
- Acute presentation
- Already taking statins or other lipid-lowering medication
- Known adverse reaction to statins
- Hepatic dysfunction
- Moderate to severe renal dysfunction
- Previous history of rhabdomyolysis
- On contraindicated medication
- Pregnancy
- Breastfeeding
- Patient choice.
Sites / Locations
- Auckland City Hospital
- Manukau Surgical Centre, Middlemore Hospital
- North Shore Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
Simvastatin
Arm Description
Placebo tablets (Inert calcium lactate)
40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
Outcomes
Primary Outcome Measures
Total complications
Complications pre-defined and graded by the Clavien-Dindo classification
Secondary Outcome Measures
Peritoneal Cytokines
Serum cytokines
Change in serum C-reactive protein (CRP)
Change in functional recovery
Full Information
NCT ID
NCT00994903
First Posted
October 13, 2009
Last Updated
November 27, 2013
Sponsor
University of Auckland, New Zealand
Collaborators
Counties Manukau Health, Waitemata District Health Board, Auckland District Health Board
1. Study Identification
Unique Protocol Identification Number
NCT00994903
Brief Title
Simvastatin in Colorectal Surgery
Acronym
StatCol
Official Title
Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Auckland, New Zealand
Collaborators
Counties Manukau Health, Waitemata District Health Board, Auckland District Health Board
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Statins (HMG-CoA reductase inhibitors) are a widely used class of cholesterol-lowering drugs that have an established role in the medical management of cardiovascular disease. Their benefits have also been shown in the surgical setting with decreased cardiovascular complications and lower perioperative mortality following cardiac and vascular surgery. There is now considerable evidence showing statins have useful pleiotropic properties that extend beyond cholesterol lowering, including anti-inflammatory, anti-oxidant, immunomodulatory and fibrinolytic effects. Growing evidence suggests these effects may be useful in attenuating the proinflammatory and metabolic stress response to surgery and the benefit of statins may extend to other surgical settings such as abdominal surgery.
Laboratory studies demonstrate the surgically-relevant benefits of statins and show they decrease peritoneal inflammation, reduce the severity of intestinal ischaemia-reperfusion injury, improve survival in models of abdominal sepsis, decrease the formation of postoperative intraperitoneal adhesions and improve the healing of colonic anastomoses. Retrospective clinical studies show statins improve outcomes in sepsis, reduce the postoperative systemic inflammatory response syndrome (SIRS) and are associated with decreased rates of surgical wound infections and postoperative respiratory complications following various non-cardiac general surgical procedures. However, no prospective studies have specifically evaluated the perioperative use of statins in abdominal surgery. Using colorectal surgery as a model for major abdominal surgery, the investigators will conduct a randomised controlled trial evaluating the effect of perioperative statin use on postoperative morbidity, local and systemic inflammatory response, and functional recovery after surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intestinal Neoplasm, Perioperative Care
Keywords
Statin, Colon, Colorectal, Intestinal Neoplasms, ERAS, Perioperative Care
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
132 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablets (Inert calcium lactate)
Arm Title
Simvastatin
Arm Type
Experimental
Arm Description
40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
Intervention Type
Drug
Intervention Name(s)
Simvastatin
Intervention Description
40mg orally, given 3-7 days pre-op and continued till 14 days post-op
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
Primary Outcome Measure Information:
Title
Total complications
Description
Complications pre-defined and graded by the Clavien-Dindo classification
Time Frame
Up to post-operative day 30
Secondary Outcome Measure Information:
Title
Peritoneal Cytokines
Time Frame
Postoperative Day 1
Title
Serum cytokines
Time Frame
Post-operative Day 1
Title
Change in serum C-reactive protein (CRP)
Time Frame
Baseline and Postoperative Day 1, 2 and 3
Title
Change in functional recovery
Time Frame
Baseline and Postoperative Day 1, 3, 7, 14, and 30
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Consecutive consenting patients undergoing elective colectomy, rectal resection, and reversal of Hartmann's procedure at Middlemore Hospital, Manukau Surgery Centre, Auckland City Hospital, and North Shore Hospital.
Exclusion criteria:
Acute presentation
Already taking statins or other lipid-lowering medication
Known adverse reaction to statins
Hepatic dysfunction
Moderate to severe renal dysfunction
Previous history of rhabdomyolysis
On contraindicated medication
Pregnancy
Breastfeeding
Patient choice.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew G Hill, MBChB MD FRACS
Organizational Affiliation
University of Auckland, New Zealand
Official's Role
Principal Investigator
Facility Information:
Facility Name
Auckland City Hospital
City
Auckland
Country
New Zealand
Facility Name
Manukau Surgical Centre, Middlemore Hospital
City
Auckland
Country
New Zealand
Facility Name
North Shore Hospital
City
Auckland
Country
New Zealand
12. IPD Sharing Statement
Citations:
PubMed Identifier
27086089
Citation
Singh PP, Lemanu DP, Soop M, Bissett IP, Harrison J, Hill AG. Perioperative Simvastatin Therapy in Major Colorectal Surgery: A Prospective, Double-Blind Randomized Controlled Trial. J Am Coll Surg. 2016 Aug;223(2):308-320.e1. doi: 10.1016/j.jamcollsurg.2016.04.004. Epub 2016 Apr 13.
Results Reference
derived
Learn more about this trial
Simvastatin in Colorectal Surgery
We'll reach out to this number within 24 hrs